$7.44
0[0.00%]
At close: Apr 23
$7.44
0[0.00%]
After Hours: 4:00PM EDT
Fulcrum Therapeutics
(NASDAQ:FULC)Latest News for Fulcrum Therapeutics Stock (NASDAQ:FULC)
Fulcrum Therapeutics Stock (NASDAQ: FULC)
Categories: All
Friday, March 29, 2024
Wednesday, March 13, 2024
Wednesday, March 06, 2024
- Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Mar 6, 2024, 1:54PM
- Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Mar 6, 2024, 11:45AM
Wednesday, February 28, 2024
- Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)Benzinga Insights - Feb 28, 2024, 3:00PM
- HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $17Benzinga Newsdesk - Feb 28, 2024, 1:13PM
- Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $15Benzinga Newsdesk - Feb 28, 2024, 10:44AM
Tuesday, February 27, 2024
Monday, February 26, 2024
Friday, January 26, 2024
Thursday, January 25, 2024
Friday, December 22, 2023
Tuesday, November 07, 2023
- Fulcrum Therapeutics Now Expects That Its Existing Cash And Equivalents To Be Sufficient To Fund Its Operating Requirements Into 2026, An Update To Prior Guidance Of Mid-2025Benzinga Newsdesk - Nov 7, 2023, 7:10AM
- Fulcrum Therapeutics Q3 EPS $(0.39) Vs $(0.51) Last Year, Sales $759.00K Miss $1.05M EstimateBenzinga Newsdesk - Nov 7, 2023, 7:05AM
- Earnings Scheduled For November 7, 2023Benzinga Insights - Nov 7, 2023, 6:34AM
Monday, November 06, 2023
Monday, September 25, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023Benzinga Insights - Sep 25, 2023, 11:00AM
- The Latest Analyst Ratings for Fulcrum TherapeuticsBenzinga Insights - Sep 25, 2023, 9:00AM
- Goldman Sachs Initiates Coverage On Fulcrum Therapeutics with Neutral Rating, Announces Price Target of $5Benzinga Newsdesk - Sep 25, 2023, 5:01AM
Thursday, September 07, 2023
Thursday, August 24, 2023
Wednesday, August 23, 2023
- Fulcrum Therapeutics To Rally Around 120%? FDA Update Removes Overhang On Pivotal ProgramVandana Singh - Aug 23, 2023, 2:31PM
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023Benzinga Insights - Aug 23, 2023, 11:00AM
- HC Wainwright & Co. Upgrades Fulcrum Therapeutics to Buy, Raises Price Target to $14Benzinga Newsdesk - Aug 23, 2023, 6:19AM
Tuesday, August 22, 2023
- Fulcrum Therapeutics shares are trading higher after the company announced the FDA lifted the clinical hold on Fulcrum's FTX-6058 for sickle cell disease.Benzinga Newsdesk - Aug 22, 2023, 3:37PM
- Crude Oil Falls; Dick's Sporting Goods Earnings Miss ViewsLisa Levin - Aug 22, 2023, 3:07PM
- Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Aug 22, 2023, 1:49PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Aug 22, 2023, 1:31PM
- Dow Falls Over 100 Points; US Existing Home Sales Decline In JulyLisa Levin - Aug 22, 2023, 12:36PM
- Why Is Fulcrum Therapeutics Stock Surging Today?Vandana Singh - Aug 22, 2023, 11:05AM
- Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023Benzinga Insights - Aug 22, 2023, 11:00AM
- Fulcrum Therapeutics, AMTD Digital, Hasbro And Other Big Stocks Moving Higher On TuesdayLisa Levin - Aug 22, 2023, 10:29AM
- Oppenheimer Reiterates Outperform on Fulcrum Therapeutics, Maintains $16 Price TargetBenzinga Newsdesk - Aug 22, 2023, 10:09AM
- US Stocks Mixed; Lowe's Posts Upbeat EarningsLisa Levin - Aug 22, 2023, 10:00AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Aug 22, 2023, 9:06AM
- Market-Moving News for August 22ndBenzinga Newsdesk - Aug 22, 2023, 7:57AM
- Stifel Upgrades Fulcrum Therapeutics to Buy, Announces $11 Price TargetBenzinga Newsdesk - Aug 22, 2023, 7:26AM
- FDA Lifts Clinical Hold On Fulcrum Therapeutics' FTX-6058 For Sickle Cell DiseaseBenzinga Newsdesk - Aug 22, 2023, 7:01AM
Thursday, August 10, 2023
Friday, August 04, 2023
Thursday, August 03, 2023
- Fulcrum Therapeutics Has Appointed Alan Musso As Chief Financial Officer, Effective August 7, 2023.Benzinga Newsdesk - Aug 3, 2023, 7:11AM
- Fulcrum Therapeutics Q2 EPS $(0.38) Beats $(0.44) Estimate, Sales $880.00K Miss $1.60M EstimateBenzinga Newsdesk - Aug 3, 2023, 7:05AM
- Earnings Scheduled For August 3, 2023Benzinga Insights - Aug 3, 2023, 6:59AM
Tuesday, May 16, 2023
Monday, May 15, 2023
- Fulcrum Therapeutics Appointed Alex C. Sapir As Chief Executive Officer And President, Effective July 1, 2023; Upon Assuming His New Role, Mr. Sapir Will Also Join Fulcrum's Board Of DirectorsBenzinga Newsdesk - May 15, 2023, 7:18AM
- Fulcrum Therapeutics Q1 EPS $(0.41) Beats $(0.46) Estimate, Sales $259.00K Miss $1.13M EstimateBenzinga Newsdesk - May 15, 2023, 7:07AM